The word "authorized" does heavy lifting in US pouch coverage, and most of it is wrong. Headlines say the FDA approved ZYN, readers hear safe, and both halves of that sentence misstate what the agency did. This explainer separates the three instruments the FDA actually issues, marketing orders, modified risk orders, and enforcement discretion, and dates the ones that exist.
Snus Watch writes for adult nicotine users: 21 and over in the US, 18 and over in Europe and the UK. Regulatory facts only on this page; the FDA's orders speak for themselves and we quote them rather than paraphrase their conclusions.
What does a PMTA marketing order actually decide?
Under the 2009 Tobacco Control Act, a new tobacco product cannot be sold in the US until the FDA authorizes its marketing through the premarket tobacco product application pathway. The legal test is population-level: taking account of users and non-users alike, the agency must find that permitting the product's marketing is appropriate for the protection of public health.
That is a balance-of-evidence judgment about a named product, its ingredients, its marketing and its likely users. It is not a finding that the product is safe, and the FDA's January 2025 release states the distinction in terms: authorization does not mean the products are safe, nor are they "FDA approved". Products authorized this way are also not approved as medicines, and authorization says nothing about any individual product helping any individual person do anything.
The January 2025 orders: what was authorized?
On 16 January 2025 the FDA authorized the marketing of 20 ZYN nicotine pouch products, the first authorizations for the pouch category. The twenty are ten varieties (Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, Wintergreen), each in 3 mg and 6 mg, from Swedish Match.
Note what the number twenty means: twenty SKUs of one brand, at two strengths. Not twenty brands, and not the category. What those two strengths mean against the wider ladder the market sells is the strength guide's whole subject. The agency's release tied the decision to the evidence in those applications, including data on the products' constituent levels relative to cigarettes and most smokeless tobacco, and study evidence on adult switching behaviour among existing tobacco users.
The June 2026 orders: what is a modified risk order?
A modified risk tobacco product order is a second, separate instrument. It permits a manufacturer to market specified products with a specific reduced-risk claim, after showing the claim is accurate for those products and that marketing them with it benefits population health.
On 30 June 2026 the FDA granted such orders for the same 20 ZYN products, the first modified risk orders for the pouch category. The authorized claim, word for word, is:
"Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
Three limits ride on that sentence. It names ZYN, not pouches. It compares against cigarettes, for a person who switches. And it is the only wording the order allows: no shorter, stronger or broader version of it is authorized marketing. This site reports the order's existence and wording as regulatory fact, which is the extent of what an authorization establishes.
What has been authorized since?
The authorized list has grown through 2026, still product by product. In August 2026, the FDA's pilot programme update added four on! nicotine pouch products. Trade reporting counted 43 authorized pouch products by August 2026. The pattern matters more than the running total: each order names a manufacturer, a product line and specific strengths or varieties, and a product not named in an order is not authorized, however similar it looks on the shelf.
Federal authorization also sits under state and local rules. States and cities layer their own flavour restrictions, tax and retail rules on top, and an FDA order does not override them.
What about everything else on the shelf?
Plenty of pouches sold in the US have no marketing order. Legally, they are not authorized for sale. Practically, enforcement has been uneven. In May 2026 the FDA announced it would not prioritize enforcement against unauthorized products whose premarket applications had been accepted and filed for review, even without a final decision. Public health groups and clinicians have sued over that guidance, arguing it lets unreviewed products stay on sale. As of this check, the guidance stands and the litigation is live, which is why the US shelf shows authorized, pending and neither, side by side.
The Europe legality tracker is the mirror image of this system: Europe regulates by country and category rule, the US by federal product licence. The UK's version of the country approach, an Act that mixes immediate rules with unused powers, is worked through in pouches under the Tobacco and Vapes Act. Readers comparing the systems now have both halves.
FAQ
Are nicotine pouches FDA approved?
No. The FDA does not approve tobacco products. It authorizes marketing for specific products under the PMTA standard, and its own January 2025 release states that authorization does not mean a product is safe or "FDA approved".
Which pouches are FDA authorized?
The first and largest block is 20 ZYN products (ten varieties, 3 mg and 6 mg), authorized in January 2025 and granted modified risk orders in June 2026. Four on! products followed in August 2026, with trade counts putting the total at 43 products by that month. Each order names exact products and strengths.
Can any brand use the modified risk claim?
No. The June 2026 orders attach to the 20 named ZYN products and to one exact sentence. Another brand quoting that sentence about its own pouches would be making an unauthorized modified risk claim.
Does FDA authorization override state flavour bans?
No. Authorization is federal permission to market; states and cities keep their own rules on flavours, taxes and retail, and those apply on top.
Why are unauthorized pouches still on sale?
Enforcement discretion. The FDA's May 2026 posture deprioritised products with applications accepted and filed, and that guidance is being challenged in court. Presence on a shelf is not evidence of authorization.
Sources
- FDA news release, FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products After Extensive Scientific Review, 16 January 2025, as reported with the release text at Patient Care Online: https://www.patientcareonline.com/view/zyn-nicotine-pouches-get-fda-nod-but-not-without-warnings
- Troutman Locke, FDA Issues First Marketing Authorization for Oral Nicotine Pouches (the APPH standard and order scope), 23 January 2025: https://www.lexblog.com/2025/01/23/fda-issues-first-marketing-authorization-for-oral-nicotine-pouches/
- FDA Modified Risk Granted Order for ZYN products (claim wording and order language), 30 June 2026, reproduced at Executive Bulletin: https://executive-bulletin.com/lifestyle-health/the-u-s-fda-authorizes-zyn-nicotine-pouches-to-be-marketed-as-modified-risk-tobacco-products
- CADCA, Nicotine Pouches: Growing Nicotine Concentrations, Growing Concern for Youth (May 2026 enforcement posture, August 2026 pilot authorizations of four on! products), October 2026: https://www.cadca.org/blog/nicotine-pouches-growing-nicotine-concentrations-growing-concern-for-youth/
- Nicokick, The FDA Authorizes 20 ZYN Nicotine Pouches (variety and strength list; June 2026 modified risk update): https://nicokick.com/us/pouch-perfect/nicoforum/fda-authorizes-marketing-of-zyn